VOR — Vor Biopharma Income Statement
0.000.00%
Last trade - 00:00
- $48.49m
- -$37.44m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 10.4 | 43.4 | 69 | 93.4 | 126 |
Operating Profit | -10.4 | -43.4 | -69 | -93.4 | -126 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -10.8 | -43.3 | -68.9 | -92.1 | -118 |
Net Income After Taxes | -10.8 | -43.3 | -68.9 | -92.1 | -118 |
Net Income Before Extraordinary Items | |||||
Net Income | -10.8 | -43.3 | -68.9 | -92.1 | -118 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.6 | -49.3 | -70.1 | -92.1 | -118 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.354 | -1.38 | -2.1 | -2.33 | -1.75 |
Dividends per Share |